每经记者｜林姿辰 每经编辑｜段炼 魏文艺 9月27日，曾被誉为"癌症早筛第一股"的诺辉健康，已经在港交所连续停牌18个月。按照港交所规定，公司可能因此被强制退市。 | 2024.4.8 | 诺辉健康在2024美国癌症研究学会发布结直肠癌早筛液体活检新技术 | | --- | --- | | 2024.1.22 | 诺辉健康发布2023年报盈喜预告:全年总收入超20亿,首年实现税后盈利 | | 2024.1.12 | 诺辉健康朱叶青：公司2023年营收较2020年实现25倍增长! | 官网资料显示，2015年诺辉健康成立于浙江杭州，是中国首家专注于高发癌症居家早筛的生物高科技公司，2021年领先行业首个实现香港联交所成功上 市，成为"中国癌症早筛第一股"，股票代码6606.HK。 诺辉健康针对中国目前高发癌症前3位中的结直肠癌和胃癌，公司已经分别上市并商业化三款明星产品：常卫清®、噗噗管®和幽幽管®。常卫清®是中国 目前唯一获得国家药监局批准的肠癌筛查产品，完成了中国目前唯一癌症筛查大规模前瞻性多中心注册临床试验，适用于40-74岁的结直肠癌高风险人 群。幽幽管®是中国目前唯一获得国家药监局批准的幽门螺杆菌消费 ...

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has emerged after a lawyer, Zhang Xiaoling, claimed that her ten years of health check reports showed no cancer risk, yet she was later diagnosed with late-stage kidney cancer. This raises questions about the reliability of routine health checks and cancer screening methods [2][3][8]. Group 1: Company Response - Aikang Guobin has conducted internal reviews and external expert evaluations, asserting that they bear no responsibility for the alleged oversight in Zhang's health checks and are open to third-party assessments [11][18]. - The company stated that Zhang's 2023 report indicated a "right kidney calcification focus" and a "possible left kidney hamartoma," contradicting her claims of no abnormalities [8][11]. - Aikang emphasized that cancer detection is a complex process influenced by various factors, including the timing of tests and the methods used, and that some cancers may not be detectable at certain stages [19][20]. Group 2: Industry Insights - The cancer screening industry is evolving, with a projected market size of $20.82 billion in 2022, expected to reach $28.93 billion in 2023, highlighting the growing demand for effective early detection methods [26][27]. - Current cancer screening technologies primarily include X-rays, CT scans, MRI scans, and ultrasound, while advanced techniques like liquid biopsies and AI-assisted imaging are being developed [27]. - Experts recommend that individuals over 40 should undergo annual ultrasound checks for urinary system cancers, as conventional blood tests may not reliably indicate kidney cancer risk [20][21].